Thomas Zindrick

Biography

Tom Zindrick, an experienced life sciences and biotechnology executive with a career spanning more than 20 years, joined Genelux Corporation as President and CEO in May 2014. Mr. Zindrick retired from Amgen Inc in 2009 after a distinguished 16 year career, and has since served as CEO of Amitech Therapeutic Solutions, Inc., a La Jolla, California based discovery and drug development company focused on commercializing allosteric kinase inhibitors, as well independent consultant to Genelux Corporation.   During his career at Amgen, he held positions of increasing responsibility, including Vice President, Associate General Counsel, and Chief Compliance Officer. As Vice President, Associate General Counsel, Mr. Zindrick led intellectual property, licensing and regulatory law teams, and served on cross-functional business and product development teams. These teams were responsible for acquisitions totaling over twenty billion dollars and the licensing and development of six therapeutic products and numerous clinical candidates. As Chief Compliance Officer, he reported to the Board of Directors and led the Corporate Compliance Program, which oversaw the compliance activities of numerous company functions including product development, manufacturing and marketing. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company.   Mr. Zindrick received his J.D. from the University of Illinois College of Law and a BA in Biology from North Central College in Naperville, Illinois.

Research Interest

Medical Devices